Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis

Abstract

Among the advanced-stage IPF patients with a more progressive status, pirfenidone decreased the rate of decline in FVC. In addition, patients treated with pirfenidone combined with NAC therapy exhibited favorable outcomes. Additional studies are needed to confirm the efficacy of this combined therapy for IPF.